HONG KONG SAR - Media OutReach Newswire - 12 September 2025 - Zentrogene Laboratory, an international genetic testing institution based in Hong Kong (under Sanai Health Industry Group 01889.HK), announced the launch of its 'Y Precision' testing technology based on Next-Generation Sequencing (NGS). This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies. It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis.
Illustration: IP Image Ambassador Dr.z
Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene's NGS-based technology achieves three breakthroughs:
Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals.
Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals.
Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.
As a pioneer in Hong Kong's genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms. This NGS breakthrough underscores its 'Technology-Driven Globalization' strategy, leveraging Hong Kong's expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family's hopes with scientific rigor.
Official Cooperation Contacts:
Telephone: +86 18051865085 (WeChat same number)
Telegram: +855 99990026
Facebook: Zentrogene
Hashtag: #Zentrogene
The issuer is solely responsible for the content of this announcement.
Zentrogene
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
